The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

A composition having cell-derived physiological activity is provided. The composition according to the present invention contains a treated product of megakaryocytes or a culture of the megakaryocytes.

Provided are cells containing exogenous antigen and uses thereof.

Invented is a method of treating degenerative diseases/injuries, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.

An object of the present invention is to provide a separation system and a separation material for efficiently separating white blood cells or mononuclear cells from a biological fluid containing blood cell components. White blood cells or mononuclear cells can be efficiently separated by contacting a biological fluid containing blood cell components with a separation material having an average fiber diameter of at least 2.0 μm but not more than 6.0 μm and an air permeability coefficient M of at least 6.2 but not more than 35 to capture white blood cells on the separation material, and recovering the captured white blood cells or mononuclear cells using a detachment solution.

Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.

Provided herein are engineered red blood cells expressing rare blood antigen group profiles, and methods of making use the same, are described. Also provided are recombinant reagent red blood cells that express or lack the expression of at least one protein (e.g., a blood group antigen) on its surface and uses thereof.

Provided herein are nucleic acid molecules that target the BCL11A enhancer functional regions, compositions comprising the nucleic acid molecules and methods for increasing fetal hemoglobin levels in a cell by disrupting BCL11A expression at the genomic level. Also provided herein are methods and compositions relating to the treatment of hemoglobinopathies by reinduction of fetal hemoglobin levels. In particular, the nucleic acid molecules target the +62, +58, and/or the +55 enhancer functional regions.

Compositions and methods involving effector cells armed with antiviral antibodies are disclosed herein. Such compositions may also include additional antiviral treatments and may be used, for example, to treat subjects having a viral infection (e.g., SARS-CoV-2).

The present invention relates to a composition comprising a supernatant of a peripheral blood mononuclear cell (PBMC) cell culture for use in the treatment or prevention of an allergy or an allergic reaction caused by the administration of at least one food and/or inhalation allergen or by the systemic administration of at least one drug to a human or mammal body.